Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway

doi:10.3389/fcell.2021.661602

HFCAS OpenIR

	Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway
	Li, Ming 1; Shan, Wulin 1; Hua, Yan 1; Chao, Fengmei 1; Cui, Yayun 1; Lv, Lei 1; Dou, Xiaoyan 1; Bian, Xing 1,2,3; Zou, Jinglu 2,3; Li, Hong2,3 ; Lin, Wenchu 2,3
	2021-05-31
发表期刊	FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
ISSN	2296-634X
通讯作者	Li, Ming(liming19831002@163.com) ; Lin, Wenchu(wenchu@hmfl.ac.cn)
摘要	Resistance to first-line chemotherapy drugs has become an obstacle to improving the clinical prognosis of patients with small cell lung cancer (SCLC). Exosomal microRNAs have been shown to play pro- and anti-chemoresistant roles in various cancers, but their role in SCLC chemoresistance has never been explored. In this study, we observed that the expression of exosomal miR-92b-3p was significantly increased in patients who developed chemoresistance. Luciferase reporter analysis confirmed that PTEN was a target gene of miR-92b-3p. The PTEN/AKT regulatory network was related to miR-92b-3p-mediated cell migration and chemoresistance in vitro and in vivo in SCLC. Importantly, exosomes isolated from the conditioned medium of SBC-3 cells overexpressing miR-92b-3p could promote SCLC chemoresistance and cell migration. Furthermore, we found that plasma miR-92b-3p levels were significantly higher in patients with chemoresistant SCLC than in those with chemosensitive SCLC, but the levels were down-regulated in patients who achieved remission. Kaplan-Meier analysis showed that SCLC patients with high miR-92b-3p expression were associated with shorter progression-free survival. Overall, our results suggested that exosomal miR-92b-3p is a potential dynamic biomarker to monitor chemoresistance in SCLC and represents a promising therapeutic target for chemoresistant SCLC.
关键词	exosome miR-92b-3p small cell lung cancer chemoresistance migration
DOI	10.3389/fcell.2021.661602
关键词[WOS]	CISPLATIN RESISTANCE ; MULTIDRUG-RESISTANCE ; PROLIFERATION ; MICRORNAS ; TUMORS
收录类别	SCI
语种	英语
资助项目	Natural Science Foundation of Anhui Province[2008085MH288] ; National Natural Science Foundation of China[81972191] ; Science and Technology Major Project of Anhui Province[18030801140] ; Fundamental Research Funds for Central University[WK9110000025] ; Fundamental Research Funds for Central University[WK9110000072] ; Fundamental Research Funds for Central University[WK9110000071] ; National Cancer Center Climbing Funds[NCC201812B036] ; High Magnetic Field Laboratory of Anhui Province
项目资助者	Natural Science Foundation of Anhui Province ; National Natural Science Foundation of China ; Science and Technology Major Project of Anhui Province ; Fundamental Research Funds for Central University ; National Cancer Center Climbing Funds ; High Magnetic Field Laboratory of Anhui Province
WOS研究方向	Cell Biology ; Developmental Biology
WOS类目	Cell Biology ; Developmental Biology
WOS记录号	WOS:000661168100001
出版者	FRONTIERS MEDIA SA
引用统计	被引频次：20[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/123915
专题	中国科学院合肥物质科学研究院
通讯作者	Li, Ming; Lin, Wenchu
作者单位	1.Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Dept Lab Diagnost,USTC, Hefei, Peoples R China 2.Chinese Acad Sci, Hefei Inst Phys Sci, High Field Magnet Lab, Hefei, Peoples R China 3.Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei, Peoples R China
通讯作者单位	中科院强磁场科学中心
推荐引用方式 GB/T 7714	Li, Ming,Shan, Wulin,Hua, Yan,et al. Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,2021,9.
APA	Li, Ming.,Shan, Wulin.,Hua, Yan.,Chao, Fengmei.,Cui, Yayun.,...&Lin, Wenchu.(2021).Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway.FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY,9.
MLA	Li, Ming,et al."Exosomal miR-92b-3p Promotes Chemoresistance of Small Cell Lung Cancer Through the PTEN/AKT Pathway".FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 9(2021).